MiRNAs: regulators of human disease

MicroRNAs (miRNAs) represent the mediators of important leading biological functions of molecular pathways in humans. They are a class of very small, non-coding RNAs; their function is the balance of the protein levels at the post-transcriptional stage. They are implicated in molecular processes and diseases, including diabetes, metabolism, autoimmune diseases, angiogenesis and tumorigenesis, and female fertility, exhibiting an altered expression profile. Any process taking place in the human organism is intertwined by miRNAs. MiRNAs have an impact on the biochemistry of pathways of the invisible molecular world. They circulate in a stable chemical configuration in body fluids (tears, serum, plasma, amniotic fluid, ascetic fluid, urine) with their molecular sequence specificity remaining unchanged. Their indisputable molecular stability ranks them as extremely vigorous potential markers in human disease. MiRNAs demonstrate a specific expressive signature, representative of the tissue specificity and the clinical staging. The shift on the concentration and expression of a miRNA reflects the course of a disease. MiRNAs may operate as oncogenes (tumor growth) or tumor suppressor (tumor reduction) genes in cancer pathways. In malignant disease, proliferation, maintenance, and progression of cancer cells is induced by the stimulation of the oncogenes or complete deactivation of the tumor suppressor gene activity.

Cancer diagnosis; miRNA expression; Endometrial cancer; miRNA.

[1] Wiemer EA.: “The role of microRNAs in cancer: No small matter”. Eur. J. Cancer, 2007, 43, 1529.

[2] Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., et al.: “Circulating MicroRNA-208b and MicroRNA- 499 reflect myocardial damage in cardiovascular disease”. Circ. Cardiovasc. Genet., 2010, 3, 499.

[3] De Rosa S., Curcio A., Indolfi C.: “Emerging Role of MicroRNas in Cardiovascular Diseases”. Circ. J., 2014, 78, 567.

[4] Yeh RW., Sidney S., Chandra M., Sorel M., Selby JV., Go AS.: “Population trends in the incidence and outcomes of acute myocardial infarction”. N. Engl. J. Med., 2010, 362, 2155.

[5] Iaconetti C., Gareri C., Polimeni A., Indolfi C.: “Non-coding RNAs: The “dark matter” of cardiovascular pathophysiology”. Int. J. Mol. Sci., 2013, 14, 19987.

[6] Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., et al.: “Circulating miRs in patients with coronary artery disease”. Circ. Res., 2010, 107, 677.

[7] Tijsen AJ., Creemers EE., Moerland PD., de Windt LJ., van der Wal AC., Kok WE., et al.: “Mir423-5p as a circulating biomarker for heart failure”. Circ. Res., 2010, 106, 1035.

[8] Ai J., Zhang R., Li Y., Pu J., Lu Y., Jiao J., et al.: “Circulating microRNA- 1 as a potential novel biomarker for acute myocardial infarction”. Biochem. Biophys. Res. Commun., 2010, 391, 73.

[9] Cheng Y., Tan N., Yang J., Liu X., Cao X., He P., et al.: “A translational study of circulating cell-free microRNA-1 in acute myocardial infarction”. Clin. Sci. (Lond.), 2010, 119, 87.

[10] Zhao H., Shen J., Medico L., Wang D., Ambrosone CB., Liu S.: “A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer”. PloS One, 2010, 5, e13735.

[11] Roth C., Rack B., Muller V., Janni W., Pantel K., Schwarzenbach H.: “Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer”. Breast Cancer Res., 2010, 12, R90.

[12] Heneghan HM., Miller N., Lowery AJ., Sweeney KJ., Newell J, Kerin MJ.: “Circulating microRNAs as novel minimally invasive biomarkers for breast cancer”. Ann. Surg., 2010, 251, 499.

[13] Taylor DD., Gercel-Taylor C.: “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer”. Gynecol. Oncol., 2008, 110, 13.

[14] Resnick KE., Alder H., Hagan JP., Richardson DL., Croce CM., Cohn DE.: “The detection of differentially expressed microRNAsfrom the serum of ovarian cancer patients using a novel re al-time PCR platform”. Gynecol. Oncol., 2009, 112, 55.

[15] Marcucci G., Mrozek K., Radmacher MD., Garzon R., Bloomfield CD.: “The prognostic and functional role of microRNAs in acute myeloid leukemia”. Blood, 2011, 117, 1121.

[16] Jiang F., Liu T., He Y., Yan Q., Chen X., Wang H., Wan X.: “MiR- 125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP531INP1 tumor suppressor in vitro and in viv.o”. BMC Cancer, 2011, 11, 425.

[17] Devor EJ., Hovey AM., Goodheart MJ., Ramachadran S., Leslie KK.: “MicroRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs”. Oncol. Rep., 2011, 26, 995.

[18] Lu Y., Govindan R., Wang L., Liu PY., Goodgame B., et al.: “MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer”. Carcinogenesis, 2012, 33, 1046.

[19] Concepcion CP., Bonetti C., Ventura A.: “The microRNA-17-92 family of microRNA clusters in development and disease”. Cancer J., 2012, 18, 262.

[20] Dorval V., Nelson PT., Hebert SS.: “Circulating microRNAs in Alzheimer’s disease: the search for novel biomarkers”. Front. Mol. Neurosci., 2013, 6, 24.

[22] Geekiyanage H., Jicha GA., Nelson PT.: “Blood serum miRNA: noninvasive biomarkers for Alzheimer’s disease”. Exp Neurol., 2012,235, 491.

[22] Im HI., Kenny PJ.: “MicroRNAs in neuronal function and dysfunction”. Trends Neurosci., 2012, 35, 325.

[23] Coolen M., Bally-Cuif L.: “MicroRNAs in brain development and physiology”. Curr. Opin. Neurobiol., 2009, 19, 461.

[24] Sheinerman KS., Umansky SR.: “Circulating cell-free microRNA as biomarkers for screening, diagnosis, and monitoring of neurodegenerative diseases and other neurologic pathologies”. Front. Cell. Neurosci., 2013, 7, 150.

[25] Bhatnagar S., Chertkow H., Schipper HM., Yuan Z., Shetty V., Jenkins S., et al.: “Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma”. Front. Mol. Neurosci., 2014, 7, 2.

[26] Zhang H., Chen Z., Wang X., Huang Z., He Z., Chen Y.: “Long noncoding RNA: a new player in cancer”. J. Hematol. Oncol., 2013, 6, 37.

[27] Ventura A., Jacks T.: “MicroRNAs and cancer: Short RNAs go a long way”. Cell, 2009, 136, 586.

[28] Di Leva G., Croce CM.: “miRNA profiling of cancer”. Curr. Opin. Genet. Dev., 2013, 23, 3.

[29] Li M, .Marin- Muller C., Bharadwaj U., Chow K.H., Yao Q., ChenC..: “MicroRNAs: control and loss of control in human physiology and disease”. World J. Surg., 2009, 33, 667.

[30] Microgene Xia., Mingua Hu.: “The role of microRNA in tumor invasion and metastasis”. J. Cancer Mol., 2010, 5, 33.

[31] Wu W., Sun M., Zou G-M., Chen J.: “MicroRNA and cancer: Current status and prospective”. Int. J. Cancer, 2006, 120, 953.

[32] Etheridge A., Lee I., Hood L., Galas D., Wang K.: “Extracellular microRNAs: a new source of biomarkers”. Mutat. Res., 2011, 717, 85.

[33] Kong YW., Ferland-McCollough D., Jackson JT., Bushell M.: “microRNAs in cancer management”. Lancet Oncol., 2012, 13, e249.

[34] Lynam-Lennon N., Maher S.G., Reynolds J.V.: “The roles of microRNAs in cancer and apoptosis”. Biol. Rev., 2009, 84, 55.

[35] Calin GA., Dumitru CD., Shimizu M., Bichi R., Zupo S., Noch E., et al.: “Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia”. Proc. Natl. Acad. Sci .USA, 2002, 99, 15524.

[36] Kumar M.S., Ereland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., et al.: “Suppression of non-small cell lung tumor development by the let-7 microRNA family”. Proc. Natl. Acad. Sci. USA, 2008, 105, 3903.

[37] Myatt S.S., Wang J., Monteiro L.J., Christian M., Ho K.K., Fusi L.,et al.: “Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer”. Cancer Res., 2010, 70, 367.

[38] Yan LX., Huang XF., Shao Q., Huang MY., Deng L., Wu QL., et al.: “MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and poor patient prognosis”. RNA, 2008, 14, 2348.

[39] Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo YY.: “MicroRNA-21 targets tumor suppressor genes in tumor invasion and metastasis”. Cell Res., 2008, 18, 350.

[40] Frankel LB., Christoffersen NR., Jacobsen A., Lindow M., Krogh A., Lund H.: “Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells”. J. Biol. Chem., 200, 283, 1026.

[41] Qin X., Yan L., Zhao X., Li C., Fu Y.: “microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer”. Oncol. Lett., 2012, 6, 1290.

[42] Yu D., Zhou H., Xun Q., Xu X., Ling J., Hu Y.: “MicroRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3”. Oncol. Lett., 2012, 3, 1221.

[43] Bostjancic E., Zidar N., Stajer D., Glavac D.: “MicroRNAs miR-1, miR-133a, miR-133b, and miR-208 are dysregulated in human myocardial infaction”. Cardiology, 2010, 115, 163.

[44] Metzler M., Wilda M., Busch K., Viehmann S., Borkhardt A.: “High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma”. Genes Chromosomes Cancer., 2004, 39, 167.

[45] Eis PS., Tam W., Sun L., Chadburn A., Li Z., Gomez MF., et al.: “Accumulation of miR-155 and BIC RNA in human B cell lymphomas”. Proc. Natl. Acad. Sci. USA, 2005, 102, 3627.

[46] Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., et al.: “Pre-B cell proliferation and lymphoblastic leukemia/high grade lymphoma in E (mu)-miR-155 transgenic mice”. Proc. Natl. Acad. Sci. USA, 2005, 103, 7024.

[47] Harris KS., Zhang Z., McManus MT., Harfe BD., Sun X.: “Dicer function is essential for lung epithelium morphogenesis”. Proc. Natl. Acad. Sci. USA, 2006, 103, 2208.

[48] Harfe BD., McManus MT., Mansfield JH., Hornstein E., Tabin CJ.: “The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb”. Proc. Natl. Acad. Sci. USA, 2005, 102, 10898.

[49] O’Rourke JR., Georges SA., Seay HR., Tapscott SJ., McManus MT., Goldhammer DJ., et al.: “Essential role for Dicer during skeletal muscle development”. Dev. Biol., 2007, 311, 359.

[50] Murchison EP., Stein P., Xuan Z., Pan H., Zhang MQ., Schultz RM., et al.: “Critical roles for Dicer in the female germline” Genes Dev., 2007, 21, 682.

[51] Otsuka M., Zheng M., Hayashi M., Lee JD., Yoshino O., Lin S. & Han J.: “Impaired microRNAs processing causes corpus luteum insufficiency and infertility in mice”. J. Clin. Invest., 2008, 118, 1944.

[52] Nagaraja AK., Andreu-Vieyra C., Franco HL., Ma L., Chen RH., Han DY., et al.: “Deletion of Dicer in somatic cells of the female reproductive tract causes sterility”. Mol. Endocrinol., 2008, 22, 2336.

[53] Carletti MZ., Christensen LK.: “MicroRNA in the ovary and female reproductive tract”. J. Anim. Sci., 2009, 87, E29.

[54] Corney DC., Flesken-Nikitin A., Godwin AK., Wang W., Nikitin AY.: “MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth”. Cancer Res., 2007, 67, 8433.

[55] Boren T., Xiong Y., Hakam A., Wenham R., Apte S., Wei Z., et al.: “MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis”. Gynecol. Oncol., 2008, 110, 206.

[56] Marsh EE., Lin Z., Yin P., Milad M., Chakravarti D., Bulun SE.: “Differential expressed of microRNA species in human uterine leiomyoma versus normal endometrium”. Fertil. Steril., 2008, 89, 1771.

[57] Miska EA.: “How microRNAs control cell division, differentiation and death”. Curr. Opin. Genet. Dev., 2005, 15, 563.

[58] Gartel AL., Kandel ES.: “Little known mediators of oncogenesis”. Semin. Cancer Biol., 2008, 18, 103.

[59] Nana-Shinkam S.P., Croce C.M.: “Non-coding RNAs in cancer initiation and progression and as novel biomarkers”. Mol. Oncol., 2011, 5, 483.

[60] Ambros V.: “The functions of animal microRNAs”. Nature, 2004, 431, 350.

[61] Lu J., Getz G., Miska EA., Alvarez-Saaverda E., Lamb J., et al.: “MicroRNA profiles classify human cancers”. Nature, 2005, 435,834.

[62] Kumar MS., Lu J., Mercer K.L., Golub T.L., Jacks T.: “Impaired microRNA processing enhances cellular transformation and tumorigenesis”.Nat. Genet., 2007, 39, 673.

[63] Giraldez A.J.: “MicroRNAs, the cell's Nepenthe: clearing the past During the maternal-to-zygotic transition and cellular Reprogramming”. Curr. Opin. Genet. Dev., 2010, 20, 369.

[64] Zhang L., Sankaran V.G., Lodish H.F.: “MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment”. Leukemia, 2012, 26, 2310.

[65] Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T.: “Identification of novel genes coding for small expressed RNAs”. Science, 2001, 294, 853.

[66] Shen J., Stass S.A., Jiang F.: “MicroRNAs as potential biomarkers in human solid tumors”. Cancer Lett., 2013, 329, 125.

[67] Pasquinelli A.E., Reinhart B.J., Slack F., Martindale M.Q., Kuroda MI. et al.: “Conservation of the sequence and temporal expressionof let- 7 hetechromic regulatory RNA”. Nature, 2000, 408, 86.

[68] Volinia S., Calin GA., Liu CG., Ambs S., Cimmino A., et al.: “A microRNA expression signature of human solid tumors defines cancergene targets”. Proc. Natl. Acad. Sci. USA, 2006, 103, 2257.[69] Esquela-Kerscher A., Slack F.J.: “Oncomirs-microRNAs with a role in Cancer”. Nat. Rev. Cancer, 2006, 6, 259.

[70] Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., et al.: “MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis”. RNA, 2008, 14, 2099.

[71] Chan JA., Krichevsky AM., Kosik KS.: “MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells”. Cancer Res., 2005, 65, 6029.

[72] Garofalo M., Quintavalle C., Romano G., Croce C.M., Condorelli G.: “miR221/222 in cancer: their role in tumor progression and response to therapy”. Curr. Mol. Med., 2012, 12, 27.

[73] Concepcion CP., Bonetti C., Ventura A.: “The microRNA-17-92 Family of microRNA clusters in development and disease”. Cancer J., 2012, 18, 262.

[74] Hausler S.F.M., Keller A., Chandran P.A., Ziegler K., Zipp K., Heuer S, et al.: “Whole-blood derived miRNA profiles as potential new tools for ovarian cancer screening”. Br. J. Cancer, 2010, 103, 693.

[75] Bartel D.P.: “MicroRNAs: genomics, biogenesis, mechanism, and Function”. Cell, 2004, 116, 281.

[76] Cheng C.J., Slack F.J.: “The duality of oncomir addiction in the maintenance and treatment of cancer”. Cancer J., 2012, 18, 232.

[77] Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C.,et al.: “APTIMA PCA3 Molecular urine test: Developmen t of a method to aid in the diagnosis of prostate cancer”. Clin. Chem., 2006, 52, 1089.

[78] Caby M.P., Lankar D., Vincendaeau-Scherrer C., Raposo G., Bonnerot C.: “Exosomal-like vesicles are present in human blood plasma”. Int. Immunol., 2005, 17, 879.

[79] Orozco A.F., Lewis D.E.: “Flow cytometric analysis of circulating Microparticles in plasma”. Cytometry A., 2010, 77, 502.

[80] Record M., Subra C., Silvente-Poirot S., Poirot M.: “Exosomes as Intercellular signalosomes and pharmacological effectors”. Biochem. Pharmacol., 2011, 81, 1171.

[81] Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K. et al.: “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases”. Cell Res., 2008, 18, 1006. [82] Teplyuk N.M., Mollenhauer B., Gabriely G., Giese A., Kim E.,Smolsky M., et al.: “MicroRNAs in cerebrospinal fluid identify glioblastoma and Metastatic brain cancers and reflect diseases activity”.Neuro. Oncol., 2012, 14, 689.

[83] Baraniskin A., Kuhnhenn J., Schlegel U., Maghnouj A., Zollner H., Schmiegel W., et al.: “Indetification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma”. Neuro. Oncol., 2011, 14, 29.

[84] Baraniskin A., Kuhnhenn J., Schlegel U., Schmiegel W., Hahn S., Schroers R.: “MicroRNAs in cerebrospinal fluid as biomarker for Disease course monitoring in primary central nervous system Lymphoma”. J. Neurooncol., 2012, 109, 239.

[85] Turchinovich A., Weiz L., Langheinz A., Burwinkel B.: “Characterization of extracellular circulating microRNAs”. Nucleic Acids Res., 2011, 39, 7223.

[86] Wang K., Zhang S., Weber J., Baxter D., Galas DJ.: “Export of microRNAs and microRNA – protective protein by mammalian cells”. Nucleic Acids Res., 2010, 38, 7248.

[87] Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M.: “Analysis of Circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription –PCR (qRT- PCR)”. Methods, 2010, 50, 298.